What's Happening?
The U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for YARTEMLEA® (narsoplimab-wuug), a treatment developed by Omeros Corporation for hematopoietic stem cell transplant-associated
thrombotic microangiopathy (TA-TMA). This J-code, effective from July 1, 2026, is expected to streamline billing and reimbursement processes for patients covered by U.S. government programs and commercial payers. YARTEMLEA is the first and only approved treatment for TA-TMA, a severe complication of stem cell transplantation characterized by systemic endothelial injury. The drug works by inhibiting MASP-2, an enzyme in the lectin pathway of complement, thereby preventing cellular injury and thrombus formation. The assignment of a permanent J-code is anticipated to reduce administrative burdens and facilitate faster access to treatment for patients.
Why It's Important?
The assignment of a permanent J-code for YARTEMLEA is significant as it provides a clear and consistent reimbursement pathway, which is crucial for ensuring timely access to this life-saving treatment. TA-TMA is a serious condition with high mortality rates, and the availability of an effective treatment without unnecessary delays can significantly improve patient outcomes. The streamlined billing process is also expected to deliver more predictable reimbursement for healthcare providers, potentially encouraging wider adoption of the treatment. This development underscores the importance of efficient healthcare administration in improving patient care and outcomes.
What's Next?
With the J-code becoming effective in mid-2026, healthcare providers and patients can expect a more straightforward process for accessing YARTEMLEA. Omeros Corporation is committed to supporting access through its YARTEMLEAssist® patient support program, which helps identify financial assistance options. Additionally, a marketing authorization application for YARTEMLEA is under review by the European Medicines Agency, with a decision expected in mid-2026. This could potentially expand the availability of the treatment to European markets, further increasing its impact on global healthcare.
